A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 24 May 2017
At a glance
- Drugs Acalabrutinib (Primary) ; Pembrolizumab
- Indications B cell lymphoma
- Focus Adverse reactions; Proof of concept
- Acronyms KEYNOTE145
- Sponsors Acerta Pharma
- 19 May 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Jul 2016 Planned number of patients changed from 324 to 187.
- 22 Jul 2016 Planned End Date changed from 1 May 2018 to 1 Apr 2021.